Florida Health Daily
SEE OTHER BRANDS

Your best source on healthcare and wellness news from Florida

Florida Health Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.

Press releases published on March 17, 2025

Jack Brewer Behavioral Health and NWF Health Partner to Combat Fatherless Crisis in Families

Jack Brewer Behavioral Health and NWF Health Partner to Combat Fatherless Crisis in Families

Faith-Based Behavioral Health Solutions Target Criminal Justice-Impacted Communities in Florida’s Panhandle TALLAHASSEE, FL, UNITED STATES, March 17, 2025 /⁨EINPresswire.com⁩/ -- Today, Jack Brewer Behavioral Health (JBBH) and NWF Health are announcing a …

'Times of My Life' Virtual Biographer App Empowers People to Share Their Advocacy Stories and Inspire Change

'Times of My Life' Virtual Biographer App Empowers People to Share Their Advocacy Stories and Inspire Change

By sharing personal journeys, challenges, and victories, users can encourage others to get involved, mobilize support, and spark meaningful change. LAKEWOOD RANCH, FL, UNITED STATES, March 17, 2025 /⁨EINPresswire.com⁩/ -- The Times of My Life virtual …

Laser Hair Removal Services Now Available at Naples Laser & Skin Aesthetics

Laser Hair Removal Services Now Available at Naples Laser & Skin Aesthetics

Naples Laser …

Inga Ellzey Releases All-New 2025 Complete Coder for Dermatology

Inga Ellzey Releases All-New 2025 Complete Coder for Dermatology

Inga Ellzey unveils the 2025 Complete Coder for Dermatology, featuring updated CPT, ICD-10-CM, and payer guidelines to minimize denials and boost revenue. CASSELBERRY, FL, UNITED STATES, March 17, 2025 /⁨EINPresswire.com⁩/ -- Inga Ellzey, founder of Inga …

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America

MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia …

MEDIROM Healthcare Technologies Inc. Announces New JPY350 Million (Approximately $2.4 Million*) Unsecured Loan Financing

MEDIROM Healthcare Technologies Inc. Announces New JPY350 Million (Approximately $2.4 Million*) Unsecured Loan Financing

TOKYO, March 17, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the “Company” or “MEDIROM”), today announced that it has obtained a new unsecured short-term bank loan in the …

Precipio Announces Q4 and year-end 2024 Shareholder Update Call

Precipio Announces Q4 and year-end 2024 Shareholder Update Call

NEW HAVEN, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4 and year end 2024 corporate update call on March 31st, 2025 at 5:00 PM ET. The call will include updates on all …

XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements

XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements

Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five transactions in 2024 Completed two whole company acquisitions to unlock shareholder value Day One’s OJEMDA™ (tovorafenib) and Zevra’s …

Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results

Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results

FARMINGDALE, N.Y., March 17, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal second quarter ended January 31, 2025, with sequential quarter improvement in revenue, gross …

NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026

NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026

PARIS and CAMBRIDGE, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering disruptive nanotherapeutic approaches to revolutionize treatment outcomes …

NANOBIOTIX renforce sa visibilité financière en amendant son accord de licence globale pour JNJ-1900 (NBTXR3) qui étend son horizon de trésorerie jusqu’à mi-2026

NANOBIOTIX renforce sa visibilité financière en amendant son accord de licence globale pour JNJ-1900 (NBTXR3) qui étend son horizon de trésorerie jusqu’à mi-2026

PARIS et CAMBRIDGE, Mass., 17 mars 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des approches fondées sur les …

Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025 Commercial launch in the PRC of generic nintedanib for the treatment of IPF and avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia expected …

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory …

Metagenomi Reports Business Updates and Full Year 2024 Financial Results

Metagenomi Reports Business Updates and Full Year 2024 Financial Results

Hemophilia A presentation at American Society of Hematology (ASH) 66th Annual Meeting demonstrated sustained Factor VIII (FVIII) activity in nonhuman primate (NHP) study for more than 16 months Leveraged hemophilia A albumin platform to achieve in vivo …

Hyperfine, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

Hyperfine, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

GUILFORD, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system— …

OrthoPediatrics Corp. Joins Crossroads Pediatric Device Consortium to Advance Pediatric Medical Device Innovation

OrthoPediatrics Corp. Joins Crossroads Pediatric Device Consortium to Advance Pediatric Medical Device Innovation

WARSAW, Ind., March 17, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its partnership with the Crossroads …

Nanox to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 31, 2025

Nanox to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 31, 2025

PETACH TIKVA, Israel, March 17, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter and fiscal …

FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

Announced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 million Transaction expected to close by mid-2025 Upon close of sale of FibroGen China, cash runway extended into 2027 Initiation of the Phase 2 monotherapy …

Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Announced positive preliminary 12-week clinical results, building on already released 4-week results, of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome autoimmune and …

AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific

AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific

VALENCIA, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced it has entered into a new Contract Manufacturing …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service